Linkage Infrastructure, Equipment And Facilities - Grant ID: LE180100043
Funder
Australian Research Council
Funding Amount
$435,279.00
Summary
High-throughput portable and wearable device fabrication facility. This project aims to establish a fabrication and characterisation facility for high-throughput production of portable, wearable and stretchable biomedical devices to accelerate the design–fabrication–evaluation process and save ‘trial-and-error’ costs during optimisation turnaround. It will apply computer-aided design for the programmable synthesis of hybrid materials for high-throughput screening of disease biomarkers, and super ....High-throughput portable and wearable device fabrication facility. This project aims to establish a fabrication and characterisation facility for high-throughput production of portable, wearable and stretchable biomedical devices to accelerate the design–fabrication–evaluation process and save ‘trial-and-error’ costs during optimisation turnaround. It will apply computer-aided design for the programmable synthesis of hybrid materials for high-throughput screening of disease biomarkers, and super-solution imaging of single molecules in live cells. This facility will provide capability for researchers pursuing industry transformation and other initiatives in the development of advanced materials, biomolecular sciences, nanotechnology, photonics and device engineering.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH150100028
Funder
Australian Research Council
Funding Amount
$3,708,510.00
Summary
ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecu ....ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecules. The initial focus would be early diagnosis of disease and point-of-care drug testing for humans and animals, but the technology platform could be used to sample food and environmental toxins. The hub expects these disruptive technologies will make Australian biotechnology, diagnostics, veterinary, agribusiness and manufacturing firms globally competitive.Read moreRead less
Ex vivo production of neutrophils. Relentless infections frequently occur in patients receiving intensive chemotherapy treatment. Chemotherapy is toxic to the bone marrow where blood cells are produced. A low white blood cell count and in particular a low neutrophil count is linked with infection in these patients. Unlike red cells and platelets, neutrophils are difficult to collect from blood donors and hence are not routinely available. In this project, we will develop a practical, cost effic ....Ex vivo production of neutrophils. Relentless infections frequently occur in patients receiving intensive chemotherapy treatment. Chemotherapy is toxic to the bone marrow where blood cells are produced. A low white blood cell count and in particular a low neutrophil count is linked with infection in these patients. Unlike red cells and platelets, neutrophils are difficult to collect from blood donors and hence are not routinely available. In this project, we will develop a practical, cost efficient process for the production of neutrophils from cord blood. Transfusion of these neutrophils should reduce the chance of patients suffering serious infection, allow them to recover faster from their chemotherapy, and reduce the need for admission to intensive care.Read moreRead less
EX VIVO PRODUCTION OF MATURE RED BLOOD CELLS FOR TRANSFUSION. This project aims to establish a practical, cost efficient biotechnology platform for the expansion and maturation of blood stem cells to produce blood transfusion products. Red blood cell production will be used as the prototype model. It is envisaged that blood bioreactors will initially supplement and ultimately replace the current blood donor based process, thus overcoming the on-going donor recruitment, retention and safety issue ....EX VIVO PRODUCTION OF MATURE RED BLOOD CELLS FOR TRANSFUSION. This project aims to establish a practical, cost efficient biotechnology platform for the expansion and maturation of blood stem cells to produce blood transfusion products. Red blood cell production will be used as the prototype model. It is envisaged that blood bioreactors will initially supplement and ultimately replace the current blood donor based process, thus overcoming the on-going donor recruitment, retention and safety issues associated with collection of single units of blood. This project is focused on providing solutions to two key technical and economical challenges: (a) achieving full maturation of red blood cells and (b) achieving at least a 100-fold intensification of the expansion and maturation process through perfusion.Read moreRead less
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza. This project aims to develop a safe and effective vaccine for Infectious Coryza using a live-attenuated vaccine approach. Infectious coryza is an acute respiratory disease of chickens and is caused by the bacterial pathogen, Avibacterium paragallinarum. Infectious Coryza can be controlled by appropriate biosecurity practises and this has been successful in the Australian context to date. However, in the USA, Europe and other e ....A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza. This project aims to develop a safe and effective vaccine for Infectious Coryza using a live-attenuated vaccine approach. Infectious coryza is an acute respiratory disease of chickens and is caused by the bacterial pathogen, Avibacterium paragallinarum. Infectious Coryza can be controlled by appropriate biosecurity practises and this has been successful in the Australian context to date. However, in the USA, Europe and other equatorial regions, infectious Coryza remains an unsolved problem. The expected outcome of this project is a cross-serovar protective vaccine to prevent infectious coryza for use in endemic countries and to act as a biosecurity measure to protect Australia's poultry industry against an incursion of this disease.Read moreRead less
Towards the development of a novel live vaccine for the control of Glässer's disease (Haemophilus parasuis), a globally significant respiratory disease of swine. Respiratory diseases are common in intensively housed pigs, costing the Australian industry millions of dollars in lost production annually. Glässer's is a highly contagious and often fatal respiratory disease of pigs. Antibiotic therapy is expensive and often results in the emergence of antibiotic resistant organisms. There is also a t ....Towards the development of a novel live vaccine for the control of Glässer's disease (Haemophilus parasuis), a globally significant respiratory disease of swine. Respiratory diseases are common in intensively housed pigs, costing the Australian industry millions of dollars in lost production annually. Glässer's is a highly contagious and often fatal respiratory disease of pigs. Antibiotic therapy is expensive and often results in the emergence of antibiotic resistant organisms. There is also a trend to move away from the use of antibiotics in food production animals. Current vaccines are based on inactivated preparations and do not offer a high level of immune protection. Therefore, there is a great need worldwide for a live vaccine for the effective control of Glässer's disease.Read moreRead less
New drugs against parasitic nematodes of livestock animals. New drugs against parasitic nematodes of livestock animals. This project aims to develop an innovative technology platform to deliver novel anti-infectives as biotechnological outcomes, using postgenomics, computing and chemistry. Advanced molecular, computer and chemistry technologies provide unprecedented opportunities to design radically new interventions against socioeconomically important infectious diseases affecting billions of a ....New drugs against parasitic nematodes of livestock animals. New drugs against parasitic nematodes of livestock animals. This project aims to develop an innovative technology platform to deliver novel anti-infectives as biotechnological outcomes, using postgenomics, computing and chemistry. Advanced molecular, computer and chemistry technologies provide unprecedented opportunities to design radically new interventions against socioeconomically important infectious diseases affecting billions of animals worldwide. Anticipated outcomes are the design of radically new chemotherapies to control parasitic diseases, the translation of fundamental research into biotechnological outcomes, international visibility of Australian science, and a solid skills- and knowledge-base in veterinary drug development.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH190100021
Funder
Australian Research Council
Funding Amount
$4,999,540.00
Summary
ARC Research Hub to Combat Antimicrobial Resistance. The ARC ITRP Research Hub to Combat Antimicrobial Resistance takes on the global challenge of antimicrobial resistance (AMR) for Australia through a world-first partnership between industry, researchers, and end users. The AMR Hub fosters a pre-commercialisation environment to address both social and laboratory-based preclinical challenges to provide a highly integrated diagnostic, pharmaceutical and end user solution to the problem of AMR. A ....ARC Research Hub to Combat Antimicrobial Resistance. The ARC ITRP Research Hub to Combat Antimicrobial Resistance takes on the global challenge of antimicrobial resistance (AMR) for Australia through a world-first partnership between industry, researchers, and end users. The AMR Hub fosters a pre-commercialisation environment to address both social and laboratory-based preclinical challenges to provide a highly integrated diagnostic, pharmaceutical and end user solution to the problem of AMR. A goal of the Hub is to support the development of new molecular diagnostic technology, improve the processes for identifying potential antibiotic compounds and assess and advise on antimicrobial stewardship with a vision to transform social and health outcomes globally.Read moreRead less